These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 30499396)

  • 1. An In Silico Investigation of Potential EGFR Inhibitors for the Clinical Treatment of Colorectal Cancer.
    Majhi M; Ali MA; Limaye A; Sinha K; Bairagi P; Chouksey M; Shukla R; Kanwar N; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2018; 18(27):2355-2366. PubMed ID: 30499396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Novel EGFR Inhibitors for the Targeted Therapy of Colorectal Cancer Using Pharmacophore Modelling, Docking, Molecular Dynamic Simulation and Biological Activity Prediction.
    Krishnan K A; Valavi SG; Joy A
    Anticancer Agents Med Chem; 2024; 24(4):263-279. PubMed ID: 38173208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-Based Virtual Screening for Defeating Drug Resistant Form of EGFR Protein.
    Sharifi A; Bagherzadeh K; Golestanian S; Amanlou M
    Comb Chem High Throughput Screen; 2016; 19(3):228-37. PubMed ID: 26768339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
    Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Imana SN; Ningsih EG; Tambunan USF
    Pak J Biol Sci; 2020 Mar; 23(4):567-574. PubMed ID: 32363843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and Pharmacological Analysis of High Efficacy Small Molecule Inhibitors of EGF-EGFR Interactions in Clinical Treatment of Non-Small Cell Lung Carcinoma: a Computational Approach.
    Gudala S; Khan U; Kanungo N; Bandaru S; Hussain T; Parihar M; Nayarisseri A; Mundluru HP
    Asian Pac J Cancer Prev; 2015; 16(18):8191-6. PubMed ID: 26745059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
    Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
    Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Phenolic Compounds as Potential Dual EGFR and COX-2 Inhibitors: Design, Semisynthesis, in vitro Biological Evaluation and in silico Insights.
    Abdelgawad MA; Musa A; Almalki AH; Alzarea SI; Mostafa EM; Hegazy MM; Mostafa-Hedeab G; Ghoneim MM; Parambi DGT; Bakr RB; Al-Muaikel NS; Alanazi AS; Alharbi M; Ahmad W; Bukhari SNA; Al-Sanea MM
    Drug Des Devel Ther; 2021; 15():2325-2337. PubMed ID: 34103896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.
    Mohyeldin MM; Akl MR; Siddique AB; Hassan HM; El Sayed KA
    Biochem Pharmacol; 2017 Feb; 126():51-68. PubMed ID: 27940262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of EGF Receptor Inhibitors That Are Selective for the d746-750/T790M/C797S Mutant through Structure-Based de Novo Design.
    Park H; Jung HY; Mah S; Hong S
    Angew Chem Int Ed Engl; 2017 Jun; 56(26):7634-7638. PubMed ID: 28493467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
    Davis GD; Vasanthi AH
    Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Docking Optimization in the Context of Multi-Drug Resistant and Sensitive EGFR Mutants.
    García-Godoy MJ; López-Camacho E; García-Nieto J; Nebro AJ; Aldana-Montes JF
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27869781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.
    Sabbah DA; Hajjo R; Sweidan K
    Curr Top Med Chem; 2020; 20(10):815-834. PubMed ID: 32124699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of small-molecule EGFR allosteric inhibitors by high-throughput docking.
    Caporuscio F; Tinivella A; Restelli V; Semrau MS; Pinzi L; Storici P; Broggini M; Rastelli G
    Future Med Chem; 2018 Jul; 10(13):1545-1553. PubMed ID: 29766737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of EGFR inhibitors as potential agents for cancer therapy: pharmacophore-based modeling, molecular docking, and molecular dynamics investigations.
    Ashiru MA; Ogunyemi SO; Temionu OR; Ajibare AC; Cicero-Mfon NC; Ihekuna OA; Jagun MO; Abdulmumin L; Adisa QK; Asibor YE; Okorie CJ; Lawal MO; Babalola MO; Abdulrasaq IT; Salau LB; Olatunji IO; Bankole MA; Daud AB; Adeyemi AO
    J Mol Model; 2023 Apr; 29(5):128. PubMed ID: 37016200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.